
    
      Main objective

        -  To evaluate safety and tolerability of adalimumab (HUMIRA) treatment, administered both
           in monotherapy and combined therapy, in rheumatoid arthritis patients under usual
           practice conditions.

      Secondary objectives

        -  To evaluate the effectiveness of the adalimumab (HUMIRA) treatment, administered both in
           monotherapy and combined therapy, in rheumatoid arthritis patients under usual practice
           conditions in accordance with SER recommendations:

        -  To evaluate the life quality associated to the adalimumab (HUMIRA) treatment,
           administered both in monotherapy and combined therapy, in rheumatoid arthritis patients
           under usual practice conditions.

        -  To describe the profile of patients who are in treatment with adalimumab (HUMIRA)
           biological therapy.
    
  